HEMLIBRA has a half-life of weeks, not hours1
Therapeutic levels of HEMLIBRA are sustained between doses and are similar across dosing regimens1,2
- Therapeutic levels of HEMLIBRA were obtained with all three dosing regimens,2 and were consistent with pharmacokinetic model predictions3
- Trough plasma concentrations of approximately 52 µg/ml were achieved from week 5, following 4 weeks of HEMLIBRA initiation at 3 mg/kg every week1
- There is the potential for patients to develop neutralising, anti-drug antibodies to HEMLIBRA. In case of clinical signs of loss of efficacy, a change of treatment should be considered1
HEMLIBRA restores the haemostatic process4
HEMLIBRA is a therapeutic bispecific monoclonal antibody, with a novel mechanism of action (MOA).1,4 It:
- Does not induce FVIII inhibitor development1
- Is clinically effective in the presence of FVIII inhibitors1,5,6
- Has a 4–5 week half-life1
Scientific mechanism of action video
Simplified animated mechanism of action video
FIXa, activated Factor IX; FVIII, Factor VIII; FX, Factor X; MOA, mechanism of action; PK, pharmacokinetics; QW, every week; Q2W, every 2 weeks; Q4W, every 4 weeks.
- HEMLIBRA Summary of Product Characteristics.
- Pipe S et al. WFH 2018 [Oral Presentation].
- Yoneyama K et al. Clin Pharmacokinet 2018;57:1123–34.
- Kitazawa T et al. Nat Med 2012;18:1570–4.
- Oldenburg J et al. N Engl J Med 2017;377:809–18.
- Young G et al. ASH 2018;322 [Abstract].
Date of preparation: August 2020